

Christer Sundström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6300525/publications.pdf>

Version: 2024-02-01

80
papers

6,251
citations

218677

26
h-index

79698

73
g-index

80
all docs

80
docs citations

80
times ranked

5688
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishment and characterization of a human histiocytic lymphoma cell line (U-937). International Journal of Cancer, 1976, 17, 565-577.	5.1	2,348
2	Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 692-701.	6.7	776
3	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo "purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 2008, 112, 2687-2693.	1.4	571
4	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem cell support: still very long survival but late relapses do occur. British Journal of Haematology, 2012, 158, 355-362.	2.5	241
5	Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology, 2005, 18, 1113-1120.	5.5	185
6	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. British Journal of Haematology, 2016, 175, 410-418.	2.5	170
7	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood, 2016, 127, 3026-3034.	1.4	168
8	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 2010, 115, 1530-1533.	1.4	167
9	Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. International Journal of Cancer, 1974, 13, 808-823.	5.1	163
10	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood, 2014, 123, 2953-2959.	1.4	90
11	Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematological Oncology, 1993, 11, 187-193.	1.7	79
12	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood, 2016, 128, 1814-1820.	1.4	75
13	Detection of tumor-specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 1994, 56, 715-720.	5.1	71
14	Monocytic origin of the human hematopoietic cell line U-937 and its convertibility to macrophages evidenced by isoenzyme mapping. International Journal of Cancer, 1983, 31, 181-186.	5.1	63
15	Epstein-Barr Virus Distribution in Hodgkin's Disease in an Unselected Swedish Population. Acta Oncologica, 1999, 38, 425-429.	1.8	57
16	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3). Blood, 2010, 115, 428-435.	2.0	56
17	TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. Journal of Pathology, 2017, 242, 129-133.	4.5	52
18	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncologica, 2018, 57, 187-194.	1.8	52

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of flow cytometry studies in B-cell non-hodgkin lymphoma. <i>Hematological Oncology</i> , 1990, 8, 1-12.	1.7	47
20	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	1.4	44
21	[¹⁸ F] FDG PET in Gastric Non-Hodgkin's Lymphoma. <i>Acta Oncologica</i> , 1997, 36, 577-584.	1.8	38
22	Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade. <i>PLoS ONE</i> , 2014, 9, e108861.	2.5	37
23	Lysis of fresh human B-lymphocyte-derived leukemia cells by interferon-activated natural killer (NK) cells. <i>International Journal of Cancer</i> , 1982, 29, 1-7.	5.1	36
24	Alterations of the <i>CD58</i> gene in classical Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 638-645.	2.8	36
25	Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. , 1997, 72, 394-397.		35
26	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 376-384.	1.3	31
27	p53 is associated with high-risk and pinpoints <i>TP53</i> missense mutations in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 796-805.	2.5	31
28	Lymphocyte predominant cells detect <i>Moraxella catarrhalis</i> -derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. <i>Nature Communications</i> , 2020, 11, 2465.	12.8	31
29	Lymphoma Incidence in a Swedish County During 1969-1987. <i>Acta Oncologica</i> , 1992, 31, 275-282.	1.8	30
30	Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. <i>Blood Advances</i> , 2021, 5, 900-912.	5.2	30
31	Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. <i>Acta Oncologica</i> , 2017, 56, 599-607.	1.8	27
32	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. , 1997, 71, 510-516.		25
33	Two courses of four weekly infusions of rituximab with or without interferon- γ : final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 2598-2607.	1.3	24
34	Prognostic relevance of serum markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. <i>European Journal of Haematology</i> , 1988, 40, 289-298.	2.2	22
35	Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype. <i>Rheumatology</i> , 2021, 60, 809-819.	1.9	21
36	High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. <i>British Journal of Haematology</i> , 2019, 184, 192-201.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	1.4	19
38	Pernicious Anaemia in Association with Argyrophil (Sevierâ€Munger) Gastric Carcinoid. <i>Scandinavian Journal of Haematology</i> , 1979, 23, 415-420.	0.0	17
39	Lysis of human B-lymphocyte-derived lymphoma/leukemia cells of established cell lines by interferon-activated natural killer (NK) cells. <i>International Journal of Cancer</i> , 1981, 28, 459-468.	5.1	16
40	A comparative study of proliferation-associated parameters in b-cell non-hodgkin lymphoma. <i>Hematological Oncology</i> , 2006, 9, 287-298.	1.7	15
41	Association between HLA-A1 and -A2 types and Epsteinâ€Barr virus status of post-transplant lymphoproliferative disorder. <i>Leukemia and Lymphoma</i> , 2016, 57, 2351-2358.	1.3	15
42	Primarily asymptomatic lowâ€grade nonâ€Hodgkin lymphomas: Prediction of symptomâ€free survival and total survival. <i>European Journal of Haematology</i> , 1989, 43, 332-338.	2.2	14
43	Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. <i>International Journal of Cancer</i> , 1992, 50, 153-160.	5.1	13
44	Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2015, 185, 1740-1748.	3.8	13
45	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. <i>British Journal of Haematology</i> , 2020, 189, 707-717.	2.5	13
46	The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues. <i>PLoS ONE</i> , 2014, 9, e115911.	2.5	13
47	Diagnostics of Malignant Lymphomas with Ultrasound Guided 1.2 MM Biopsy-Gun. <i>Acta OncolÃ³gica</i> , 1994, 33, 33-37.	1.8	11
48	Phenotypic and cytogenetic characteristics of a new Epsteinâ€Barr virus negative cell line (SKW 4) derived from a Bâ€Cell lymphoma. <i>Hematological Oncology</i> , 1983, 1, 277-295.	1.7	11
49	Numerous Ontogenetic Roads to Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1454-1458.	3.8	11
50	CD30 expression and survival in posttransplant lymphoproliferative disorders. <i>Acta OncolÃ³gica</i> , 2020, 59, 673-680.	1.8	11
51	Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. <i>Blood Advances</i> , 2022, 6, 152-164.	5.2	11
52	PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. <i>Acta OncolÃ³gica</i> , 2021, 60, 531-538.	1.8	10
53	The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin-3 or granulocyte-macrophage colony stimulating factor. <i>British Journal of Haematology</i> , 1999, 104, 516-522.	2.5	9
54	Serum levels of soluble vascular cell adhesion moleculeâ€1 (sVCAMâ€1) are elevated in advanced stages of nonâ€Hodgkin's lymphomas. <i>European Journal of Haematology</i> , 1999, 62, 202-209.	2.2	9

#	ARTICLE	IF	CITATIONS
55	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their <i>ALK</i> , <i>DUSP22</i> and <i>TP63</i> Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. <i>Blood</i> , 2017, 130, 822-822.	1.4	9
56	Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunocytochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study. <i>Blood</i> , 2010, 116, 993-993.	1.4	8
57	Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2017, 98, 52-56.	2.2	7
58	Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. <i>Journal of Rheumatology</i> , 2015, 42, 690-694.	2.0	6
59	Immunophenotype analysis of B-cell lymphoma and immunocytoma. <i>Apmis</i> , 1989, 97, 1025-1032.	2.0	5
60	Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T01). <i>Blood</i> , 2010, 116, 3566-3566.	1.4	5
61	Alterations of the Immunoglobulin Heavy Chain Locus in Progressive B-cell Lymphomas. <i>Acta Oncologica</i> , 1998, 37, 193-200.	1.8	4
62	Sporadic occurrence of non-diagnosed IgG4-related disease in lymphoma patients with a previous Sjögren's syndrome diagnosis. <i>Acta Oncologica</i> , 2016, 55, 1139-1144.	1.8	4
63	Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T01). <i>Blood</i> , 2010, 116, 3565-3565.	1.4	4
64	Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. <i>Blood</i> , 2012, 120, 747-747.	1.4	3
65	Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases - A Possible Association with High Rheumatoid Arthritis Disease Activity. <i>Cancers</i> , 2022, 14, 1509.	3.7	3
66	Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis. <i>Acta Oncologica</i> , 2019, 58, 1655-1659.	1.8	2
67	Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders. <i>Acta Oncologica</i> , 2021, 60, 771-778.	1.8	2
68	R-CHOEP-14 - 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years.. <i>Blood</i> , 2010, 116, 2805-2805.	1.4	2
69	Loss of function mutations of <i>BCOR</i> in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1080-1090.	1.3	2
70	IgE-producing low-grade non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 1988, 41, 388-395.	2.2	1
71	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but. <i>British Journal of Haematology</i> , 2012, 158, 815-816.	2.5	1
72	Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies. <i>Immunobiology</i> , 2021, 226, 152069.	1.9	1

#	ARTICLE	IF	CITATIONS
73	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinicopathological and immunohistochemical population-based study of 32 patients. <i>International Journal of Cancer</i> , 1997, 71, 510-516.	5.1	1
74	Rituximab (R) in Combination with Interferon- α 2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group. <i>Blood</i> , 2012, 120, 794-794.	1.4	1
75	Pre-treatment health-related quality of life parameters have prognostic impact in patients ≥ 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENABERIT) experience. <i>Hematological Oncology</i> , 2022, 40, 23-31.	1.7	1
76	A5.27...Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A40.2-A40.	0.9	0
77	Lymphomas in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: A Report from the Swedish Biologics Register (ARTIS) and the ARTIS Study Group 1998-2006. <i>Blood</i> , 2008, 112, 3754-3754.	1.4	0
78	MYC + Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report. <i>Blood</i> , 2011, 118, 594-594.	1.4	0
79	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. <i>Blood</i> , 2014, 124, 2994-2994.	1.4	0
80	Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment. <i>Acta Oncologica</i> , 2022, 61, 824-829.	1.8	0